Continual reassessment and related designs in dose-finding studies

Statistics in Medicine

Volumn 30, Issue 17, 2011, Pages 2057-2061

  Iasonos, Alexia ^a   O'Quigley, John ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BAYES THEOREM; CONFLICT OF INTEREST; CONTINUAL REASSESSMENT METHOD; DOSE CALCULATION; EDITORIAL; FACTORIAL DESIGN; HARM REDUCTION; HUMAN; MATHEMATICAL MODEL; MAXIMUM LIKELIHOOD METHOD; MAXIMUM TOLERATED DOSE; PATIENT SELECTION; RANDOMIZATION; RISK ASSESSMENT; SAMPLE SIZE; SENSITIVITY ANALYSIS; STUDY DESIGN;

CLINICAL TRIALS, PHASE I AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MAXIMUM TOLERATED DOSE; MODELS, STATISTICAL; RESEARCH DESIGN;

EID: 79959997003     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.4215     Document Type: Editorial

References (20)

1. Rogatko A, Schoeneck D, Jonas W, Tighiouart M, Khuri FR, Porter A. Translation of innovative designs into phase I trials. Journal of Clinical Oncology 2007; 25(31):4982-4986.
2. Ahn C. An evaluation of phase I cancer clinical trial designs. Statistics in Medicine 1998; 17(14):1537-1549.
3. Piantadosi S, Liu G. Improved designs for dose escalation studies using pharmacokinetic measurements. Statistics in Medicine 1996; 15(15):1605-1618.
4. Whitehead J, Williamson D. Bayesian decision procedures based on logistic regression models for dose-finding studies. Journal of Biopharmaceutical Statistics 1998; 8:445-467.
5. Thall PF, Lee JJ, Tseng CH, Estey EH. Accrual strategies for phase I trials with delayed patient outcome. Statistics in Medicine 1999; 18(10):1155-1169.
6. Storer B. An evaluation of phase I clinical trial designs in the continuous dose-response setting. Statistics in Medicine 2001; 20(16):2399-2408.
7. O'Quigley J, Pepe M, Fisher L. Continual reassessment method: a practical design for phase 1 clinical trials in cancer. Biometrics 1990; 46(1):33-48.
8. Goodman SN, Zahurak ML, Piantadosi S. Some practical improvements in the continual reassessment method for phase I studies. Statistics in Medicine 1995; 14(11):1149-1161.
9. Iasonos A, Wilton AS, Riedel ER, Seshan VE, Spriggs DR. A comprehensive comparison of the continual reassessment method to the standard 3 + 3 dose escalation scheme in Phase I dose-finding studies. Clinical Trials 2008; 5:465-477.
10. O'Quigley J. Another look at two phase I clinical trial designs (with commentary). Statistics in Medicine 1999; 18:2683-2692.
11. Reiner E, Paoletti X, O'Quigley J. Operating characteristics of the standard phase 1 clinical trial design. Computational Statistics and Data Analysis 1999; 30:303-315.
12. Babb J, Rogatko A, Zacks S. Cancer phase I clinical trials: efficient dose escalation with overdose control. Statistics in Medicine 1998; 17(10):1103-1120.
13. Iasonos A, Zohar S, O'Quigley J. Two-stage continual reassessment method that determines dose-escalation based on individual toxicity grades. Society of Clinical Trials 31st Annual Meeting, 2010 (abstract P94).
14. O'Quigley J. Theoretical study of the continual reassessment method. Journal of Statistical Planning and Inference 2006; 136:1765-1780.
15. Cheung YK. Coherence principles in dose-finding studies. Biometrika 2005; 92(4):863-873.
16. Garrett-Mayer E. The continual reassessment method for dose-finding studies: a tutorial. Clinical Trials 2006; 3(1):57-71.
17. O'Quigley J, Zohar S. Experimental designs for phase I and phase I/II dose-finding studies. British Journal of Cancer 2006; 94:609-613.
18. Yin G, Yuan Y. Bayesian model averaging continual reassessment method in phase I clinical trials. Journal of the American Statistical Association 2009; 104(487):954-968.
19. O'Quigley J. Retrospective analysis of sequential dose-finding designs. Biometrics 2005; 61:749-756.
20. Houede N, Thall PF, Nguyen H, Paoletti X, Kramar A. Utility-based optimization of combination therapy using ordinal toxicity and efficacy in phase I/II trials. Biometrics 2010; 66(2):532-540.